Alps Group Inc ALPS
Company Profile ↓Company Overview
Alps Group Inc (ALPS) is a publicly traded company listed on NasdaqGM with a market capitalization of $63.23M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 68.7%, reflecting efficient use of shareholder capital.
Revenue has grown at a 10.5% CAGR over the past five years.
Recent Developments
- Mar 2026 Revenue of $4.86M (+44.1% YoY); net profit $-2.01M.
- Trailing 12 Months Year-on-year growth — revenue +44.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 10.5%, profit CAGR -58.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.55% |
| 1 Year: | 44.06% |
Compounded Profit Growth
| 5 Years: | -58.48% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -84.96% |
| 6 Months: | -59.04% |
| 3 Months: | -46.38% |
| 1 Month: | -7.23% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.93 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 68.7%.
- Compounding revenue at 10.5% over 5 years.
CONS
- Earnings shrank at -58.5% CAGR over 5 years.
- Trading 85.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 3.59M | 2.40M | 3.37M | 4.86M |
| Cost of Revenue | 1.62M | 1.80M | 2.07M | 3.30M |
| Gross Profit | 1.98M | 598.93K | 1.30M | 1.56M |
| Operating Expenses | 2.46M | 2.83M | 3.44M | 4.25M |
| Operating Income | -485.02K | -2.24M | -2.13M | -2.70M |
| EBITDA | 363.17K | -1.45M | -1.35M | -901.36K |
| Interest Expense | 46.61K | 42.84K | 48.28K | 50.46K |
| Pretax Income | -582.06K | -2.40M | -2.53M | -2.08M |
| Tax Provision | 147.80K | -7.41K | 95.56K | 5.14K |
| Net Income | -729.16K | -2.30M | -2.51M | -2.01M |
| Diluted EPS | -0.01 | -0.01 | -0.02 | -0.02 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Total Assets | 4.80M | 6.70M | 7.13M | 6.97M |
| Current Assets | 1.09M | 1.28M | 1.49M | 1.97M |
| Cash & Equivalents | 261.81K | 460.47K | 318.93K | 607.47K |
| Inventory | 417.41K | 364.14K | 556.22K | 492.88K |
| Receivables | 20.89K | 74.02K | 45.53K | 135.19K |
| Total Liabilities | 3.17M | 5.25M | 8.25M | 10.20M |
| Current Liabilities | 2.98M | 5.06M | 7.49M | 5.48M |
| Long Term Debt | - | - | - | - |
| Total Debt | 520.40K | 507.57K | 961.88K | 559.27K |
| Total Equity | 1.66M | 1.57M | -888.56K | -2.92M |
| Shares Outstanding | 166.34M | 166.34M | 166.34M | 166.40M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating Cash Flow | -113.57K | -1.37M | -1.61M | -2.58M |
| Investing Cash Flow | -288.29K | -1.71M | -100.06K | -64.49K |
| Financing Cash Flow | 212.92K | 3.28M | 1.87M | 2.93M |
| Capital Expenditure | -274.47K | -221.32K | -83.77K | -56.41K |
| Free Cash Flow | -388.04K | -1.59M | -1.69M | -2.63M |
| Net Change in Cash | -188.94K | 197.56K | 157.75K | 291.35K |
Ratios (Annual)
Figures in %.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Margin % | 55.0% | 24.9% | 38.6% | 32.1% |
| Operating Margin % | -13.5% | -93.0% | -63.3% | -55.5% |
| Net Margin % | -20.3% | -95.9% | -74.6% | -41.4% |
| ROE % | -44.0% | -147.0% | 282.9% | 68.7% |
| ROCE % | -26.6% | -135.9% | 599.4% | -180.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Millennium Management Llc | 0.22% | 362.23K | $144.89K |
| 2 | MMCAP International, Inc. SPC | 0.03% | 54.00K | $21.60K |
| 3 | Citadel Advisors Llc | 0.03% | 42.16K | $16.86K |
| 4 | Jones Financial Companies, L.L.L.P. | 0.01% | 24.95K | $9.98K |
| 5 | Susquehanna International Group, LLP | 0.01% | 23.53K | $9.41K |
| 6 | Aristeia Capital, LLC | 0.01% | 11.85K | $4.74K |
| 7 | SkyView Investment Advisors, LLC | 0.01% | 10.00K | $4.00K |
| 8 | UBS Group AG | - | 1.64K | $654 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALPS
Alps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business Update
Revenue Grew 44% to $4.9 Million, Led by Continued Growth Across Cellular Therapy, Medical Testing, Laboratory and Aesthetics Beauty Services, and Healthcare Products Began Trading on the Nasdaq Global Market Under the Ticker Symbol "ALPS" …
Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia
Agreement Marks Company’s Expansion into Precision Oncology Testing, with the Goal of Establishing Malaysia's First Clinically Validated PDO PlatformKUALA LUMPUR, Malaysia, June 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Co…
Alps Group Inc Expands MyGenome Accreditation to Include Whole Genome Sequencing Under MS ISO 15189:2022
MyGenome Joins a Limited Number of Southeast Asian Laboratories Delivering WGS Under Internationally Recognized Clinical Standards, Strengthening its Position in Southeast Asian GenomicsKUALA LUMPUR, Malaysia, June 09, 2026 (GLOBE NEWSWIRE)…
Alps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
KUALA LUMPUR, Malaysia, May 19, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specia…
Alps Group Appoints Former Ernst & Young Partner to Board of Directors, Strengthening Governance and Capital Markets Oversight
KUALA LUMPUR, Malaysia, April 17, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a biotechnology research and healthcare platform focused on predictive…
Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol
KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform speci…
ALPS — Frequently Asked Questions
What is the current share price of Alps Group Inc (ALPS)?
As of 2026-09-19 21:16 PDT, Alps Group Inc (ALPS) trades at $0.38 on NasdaqGM. Its 52-week range is $0.27 to $2.56.
What is the market capitalisation of ALPS?
Alps Group Inc (ALPS) has a market capitalisation of $63.23M on NasdaqGM.
What is the P/E ratio of ALPS?
ALPS trades at a trailing price-to-earnings (P/E) ratio of -19.00. Its price-to-book (P/B) ratio is 8.89.
What is the return on equity (ROE) of ALPS?
ALPS has a return on equity (ROE) of 68.67%. Its return on capital employed (ROCE) is -136.00%.
Is ALPS a good stock to buy?
This page provides a data-driven analysis of Alps Group Inc (ALPS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.